Skip to content

Clinical trials

Axial Spondyloarthritis trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Axial Spondyloarthritis Clear all

176 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20051
20081
20092
20112
20132
20147
201512
201612
201713
20187
201912
202011
202114
202211
202318
202420
202515
202614

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed86
Unknown status26
Recruiting26
Not yet recruiting14
Active, not recruiting11
Terminated9
Withdrawn2
Enrolling by invitation1
Available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals8
Assistance Publique - Hôpitaux de Paris7
UCB Biopharma SRL7
AbbVie6
Centre Hospitalier Universitaire de Besancon4
Acibadem University3
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh3
Biogen3
Singapore General Hospital3
The Danish Center for Expertise in Rheumatology3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Axial Spondyloarthritis176
Spondylitis, Ankylosing55
Arthritis, Rheumatoid32
Arthritis, Psoriatic31
Spondylarthritis18
Non-Radiographic Axial Spondyloarthritis16
Crohn Disease11
Arthritis9
Lupus Erythematosus, Systemic6
Colitis, Ulcerative5

Trials

Showing 51 to 75 of 176. Each trial links to its page on Pharma Observatory.

76 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.